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Abstract
Background: Gastric cancer is usually diagnosed in an advanced stage of disease and treatment options are sparse.
Trastuzumab was recently approved for metastatic or locally advanced carcinomas arising in the stomach or in the
gastroesophageal junction in patients with HER2-positive tumors. However, data on the frequency of HER2-positive
cases among Brazilian patients are limited. Our aim was to characterize HER2 protein and gene status in a series of
Brazilian patients with gastric cancer and to evaluate its association with clinicopathological data.
Methods: Histological slides from 124 primary gastrectomies were reviewed and their pathological reports were
retrieved from the files at a Brazilian university hospital. Automated immunohistochemistry for HER2 was performed on
whole-tissue sections from each tumor. HER2-equivocal cases by immunohistochemistry were submitted to automated
dual in situ hybridization for gene amplification evaluation. HER2 status was confronted with clinicopathological
parameters in order to assess statistically significant associations.
Results: Immunohistochemistry analysis revealed that 13/124 cases (10.5 %) were HER2 positive (3+), 10/124 cases
(8.1 %) were equivocal (2+) and 101/124 cases (81.4 %) were negative, being 7 cases 1+. None of the equivocal
cases showed gene amplification. The overall HER2 positivity rate was 10.5 %. There was an association between
HER2 expression and Laurén’s intestinal histological subtype (P = 0.048), well to moderately differentiated tumors
(P = 0.004) and presence of lymphovascular invasion (P = 0.031). No association was found between HER2 status
and tumor topography.
Conclusions: Confronted with data published by other authors, the lower percentage of HER2-positive cases found in
our series might be partially explained by the lower frequency of tumors arising at the gastroesophageal junction in
comparison with distal gastric carcinomas in Brazilian patients. This could also account for the lack of statistically
significant association between HER2 status and tumor topography in our study.
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Background
About one million new cases of gastric cancer (GC) are
estimated to occur each year in the world, corresponding
to 8 % of all cancer diagnoses globally [1, 2]. GC is also
considered the second leading cause of cancer-related
deaths worldwide and over 700,000 deaths are expected
to occur due to this disease annually [1, 3]. However, the
distribution of patients with GC in different parts of the
globe is not homogeneous: over 70 % of new cases and
deaths occur in developing countries. The highest inci-
dence rates are found in Eastern Asia, Eastern Europe,
and South America [1]. The National Institute of Cancer
of Brazil estimates that GC comprises over 5 % of all
malignancies in this country [4].
Treatment options for GC are generally limited, since it
is usually diagnosed at an advanced stage of disease and,
therefore, the five-year survival rate is consistently low,
around 20 % in most parts of the world [2, 5]. According
to the ToGA study, a recent phase III international ran-
domized trial, treatment in combination of chemotherapy
and trastuzumab (TZB) has significantly improved survival
in patients with HER2-positive advanced GC [6]. TZB is a
recombinant monoclonal antibody targeting HER2, a
transmembrane protein which belongs to the family of
human epidermal growth factor receptors [7]. HER2 intra-
cellular domain shows tyrosine kinase activity, capable of
generating intracytoplasmic second messengers that coord-
inate nuclear expression of genes associated with angiogen-
esis, cell proliferation, and survival [8]. Overexpression of
the HER2 protein, a product of a proto-oncogene situated
at chromosome 17, has been associated with carcinogen-
esis and tumor progression of breast, ovary, salivary glands,
prostate and gastrointestinal tract cancers [9].
Based on ToGA trial results, international regulatory
agencies have recently approved the use of TZB in HER2-
positive metastatic or locally advanced carcinomas arising
in the stomach or in the gastroesophageal junction (GEJ)
[10]. Carcinomas from eligible patients for treatment with
TZB must present HER2-positive status, attested by pro-
tein overexpression (score 3+) by immunohistochemistry
(IHC) or gene amplification by in situ hybridization
(ISH) for tumors with equivocal IHC results (score 2+)
[11, 12]. Since then, many studies have focused on pre-
senting the frequency of HER2-positive GC in different
populations, with a wide variation on methods used for
protein and gene detection. Therefore, results remark-
ably range from 2 to 45 % of HER2 overexpression in
GC series [13–17]. A large systematic review including
data from 49 studies found a median rate of 18 % of
HER2 positivity in 11,337 patients with GC [18]. Never-
theless, the prevalence of HER2-positive cases among
Brazilian patients remains unknown, with few data pub-
lished [19–26]. Since the Brazilian public health system
has not yet endorsed the use of TZB for GC treatment
in this country, we believe that the detection of HER2-
positive GC in Brazilian patients may provide scientific
basis for the establishment of new public health policies
and define better clinical protocols to improve treat-
ment of these patients in Brazil.
Therefore, in the present study, we aimed to characterize
HER2 expression in GC in a series of Brazilian patients,
using whole-tissue tumor sections from surgical speci-
mens, and to evaluate the association between HER2
protein and gene status with clinicopathological data.
Methods
The present study was approved by the Ethics Committee
of our institution (Comitê de Ética e Pesquisa COEP-
UFMG) under CAAE protocol number 32898114.9.0000.
5149. Written informed consent was obtained in accord-
ance with the institutional guidelines.
We studied 142 consecutive patients who underwent pri-
mary gastrectomy between 2007 and 2011 at the Clinics
Hospital, Federal University of Minas Gerais, Brazil, whose
histopathological diagnosis was GC. None of the patients
had received neoadjuvant chemotherapy or other type of
treatment for their tumor prior to surgery. All 142 cases
had their pathological reports retrieved and, in order to
confirm the diagnosis of GC, the original hematoxylin-
eosin stained slides were simultaneously reviewed by two
pathologists (RSL and MMDAC), one of which is an
expert in gastrointestinal pathology (MMDAC). Clinical
data (patients’ age and gender) and pathological parame-
ters (tumor topography, maximum tumor diameter, stage,
histological grade and subtype, presence of lymphovascu-
lar and blood-vessel invasion) were recorded. Tumors
were divided into two groups according to gastric topog-
raphy: distal and proximal tumors, the latter category
included carcinomas from the GEJ. The TNM system
criteria and recomendations from the 7th Edition of the
American Joint Committee on Cancer Staging Manual
were used for tumor staging [27, 28]. The index of glandu-
lar formation and cytologic pleomorphism were consid-
ered for histological grading into well, moderately or
poorly differentiated tumors. Laurén’s histologic classifica-
tion system was used for tumor subtyping [29].
New 4 μm-thickness whole-tissue sections were ob-
tained from formalin fixed paraffin embedded tumor sam-
ples and submitted to automated IHC, using a BenchMark
XT™ platform (Ventana Medical Systems, Arizona, USA)
and the prediluted primary rabbit monoclonal antibody
anti-HER2/neu (4B5 clone). All slides were subsequen-
tially counterstained with hematoxylin. A pre-tested
HER2-positive breast cancer sample was used as exter-
nal positive control. Eighteen cases did not contain
enough tumor tissue for subsequent IHC protocols and
were excluded from this study, resulting in 124 appro-
priate cases for analysis.
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Three pathologists (RSL, HG and CBN) all at once ana-
lyzed immunostained slides using a multi-head microscope
and obtained a consensus score for HER2 expression ac-
cording to Hofmann’s and Rüschoff ’s recommendations
for GC surgical specimens [11, 12]. The cases were catego-
rized into four groups (0, 1+, 2+ and 3+), depending on the
extension and intensity of the expression: 0, no reactivity,
or membranous reactivity in < 10 % of cells; 1+, faint/barely
perceptible membranous reactivity in > 10 % of cells, and
cells are reactive only in part of their membrane; 2+, weak
to moderate complete or basolateral membranous reactiv-
ity in > 10 % of cells; 3+, strong complete or basolateral
membranous reactivity in > 10 % of cells [11]. Only a mem-
branous pattern of expression was suitable for evaluation.
The cases included into the 3+ category were considered
positive for HER2 protein overexpression, whereas 0 and
1+ cases were regarded as negative.
Cases scored as 2+ were considered equivocal for HER2
protein expression and new 4 μm-thickness whole-tissue
sections were submitted to silver brightfield in situ
hybridization (SISH) using the same automated platform
(BenchMark XT™) and the INFORM HER2 Dual ISH
DNA Probe Cocktail assay (Ventana Medical Systems, Ari-
zona, USA). The HER2 and chromosome 17 (CEP17) copy
numbers were counted in 20 nonoverlapping nuclei con-
currently by two observers (RSL and CBN). HER2 genomic
profile was defined as non-amplified if the mean HER2/
CEP17 ratio was <2.0 and amplified if the HER2/CEP17
ratio was ≥2.0. If the ratio fell between 1.8 and 2.2, an
additional 20 nuclei were scored and the overall ratio
calculated. IHC 2+ cases showing gene amplification by
SISH and IHC 3+ cases were both considered positive for
HER2 final status [11, 12].
The statistical analysis was performed using the SPSS
version 19.0 software (SPSS Inc., Chicago, IL). The Pearson
chi-square test was used to correlate IHC results and
HER2 final status with clinicopathological parameters. All
P values were two-sided, and P < 0.05 was considered sta-
tistically significant.
Results
Clinicopathological characteristics and their association
with HER2 final status and IHC scores are shown in
Table 1. Patients’ age at diagnosis ranged from 28 to
92 years (median: 62.33 years), and there were 64 males
(51.6 %) and 60 females (48.4 %) among 124 patients in-
cluded in this study. Tumors were preferably identified at
the distal stomach (80.6 %) in comparison with tumors
arising in the gastric cardia or from the GEJ. Tumor size
varied between 0.5 and 14.0 cm (average, 5.31 cm) and
advanced tumors (pT2, pT3 and pT4 categories) accounted
for 107 cases (86.3 %). According to histological grading,
13 cases (10.5 %) were well-differentiated, 45 cases (36.3 %)
moderately differentiated, and 66 cases (53.2 %) poorly
differentiated tumors. Laurén’s intestinal histological sub-
type was the most frequently diagnosed, accounting for 61
cases (49.2 %). Diffuse and mixed subtypes were observed
in 21 (16.9 %) and 33 (26.6 %) cases, respectively. The nine
remaining cases (7.3 %) were classified as indeterminate.
Lymphovascular invasion was found in 94 cases (75.8 %),
and 85 patients (68.5 %) had lymph node metastasis at
diagnosis, with an average of 9.27 positive nodes per case
(range, 1 to 63 positive nodes).
Immunohistochemical analysis revealed 13 positive
cases (3+; 10.5 %) for HER2 protein overexpression
(Fig. 1a), 10 equivocal cases (2+; 8.1 %) (Fig. 1b) and 101
negative cases (81.4 %), 7 of which were scored 1+ (5.6 %)
(Fig. 1c). Median age at diagnosis tended to increase ac-
cording to HER2 status (negative, 61.76 years; equivocal,
66.3 years; and positive, 68.58 years), although this did not
reach statistical significance. None of the patients in the
IHC 3+ category were younger than 46 years of age and
the oldest patient in the series (a 92 year old woman) was
among them. There was no association between HER2 ex-
pression and patients’ gender.
There was a positive association between HER2 pro-
tein expression and well to moderatly differentiated
tumors (P < 0.001), as well as with Laurén’s intestinal
subtype (P = 0.009).
Tumors arising in the distal stomach accounted for
76.9 % of IHC 3+ cases, while 23.1 % where found in the
gastric cardia or in the GEJ, but this variation was not sta-
tistically significant. No IHC 3+ tumor showed a diffuse or
indeterminate morphology and only two (15.4 %) were
considered poorly differentiated carcinomas. Every IHC 3+
tumor showed lymphovascular invasion and they were all
diagnosed at an advanced stage of disease, mainly in the
pT3 category (76.9 %). Eleven cases (84.6 %) were positive
for lymph node metastasis, with an average of 7.5 positive
nodes per case. However, no statistical significance was ob-
served between HER2 protein overexpression and pT, pN
or pM status.
Compared to IHC 3+ cases, HER2-equivocal tumors
(2+) presented a slightly similar profile when morpho-
logical data was taken into account. No case showed dif-
fuse or indeterminate histology, with a predominance of
intestinal subtype (9 cases, 90.0 %) and moderately
differentiated tumors (8 cases, 80.0 %). The majority of
tumors in this setting also compromised the distal
stomach and were diagnosed at an advanced stage of
disease (9 cases, 90.0 %). However, there was a decrease
in the proportion of cases showing lymphovascular in-
vasion and lymph node metastasis (6 cases, 60.0 %) in
comparison with numbers found among IHC 3+ cases
(13 cases, 100.0 % and 11 cases, 84.6 %, respectively).
HER2-negative carcinomas (scores 0 and 1+) aggregated
all tumors with a diffuse or indeterminate morphology as
well as the majority of those with a poorly differentiated
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histological grade and early stage of the disease at
diagnosis.
IHC 2+ cases were submitted to SISH but no gene amp-
lification was detected. Therefore, cases with a final HER2-
positive status were exclusively composed by IHC 3+
tumors, representing 10.5 % of all GC in this series. HER2
positivity was associated with intestinal subtype (P = 0.048),
well to moderately differentiated tumors (P = 0.004) and
presence of lymphovascular invasion (P = 0.031).
Regarding intratumoral HER2 protein heterogeneity,
the extension of IHC 3+ areas ranged from 10 to 99 %
of positive neoplastic cells (Fig. 1d). There was also a
Table 1 Association between HER2 status and clinicopathological parameters
Overall HER2 positive HER2 negative P value HER2 (3+) HER2 (2+) HER2 (0, 1+) P value
n = 124 (%) 13(10.5) 111 (89.5) 13(10.5) 10 (8.1) 101(81.4)
Age at diagnosis 0.803 0.590
≥60 years 82 (66.1) 9 73 9 8 65
<60 years 42 (33.9) 4 38 4 2 36
Gender 0.865 0.459
Male 64 (51.6) 7 57 7 7 50
Female 60 (48.4) 6 54 6 3 51
Tumor topography 0.720 0.709
Distal stomach 100(80.6) 10 90 10 9 81
Proximal stomach/GEJ 24 (19.4) 3 21 3 1 20
Histological subtype 0.048 0.009
Intestinal 61 (49.2) 11 50 11 9 41
Diffuse 21 (16.9) 0 21 0 0 21
Mixed 33 (26.6) 2 31 2 1 30
Unditermined 9 (7.3) 0 9 0 0 9
Histological grade 0.004 <0.001
Well 13 (10.5) 4 9 4 1 8
Moderately 45 (36.3) 7 38 7 8 30
Poorly 66 (53.2) 2 64 2 1 63
Lymphovascular invasion 0.031 0.060
Positive 94 (75.8) 13 81 13 6 75
Negative 30 (24.2) 0 30 0 4 26
Blood-vessel invasion 0.395 0.170
Positive 44 (35.5) 6 38 6 1 37
Negative 80 (64.5) 7 73 7 9 64
pT status 0.271 0.165
pT1 17 (13.7) 0 17 0 1 16
pT2 32 (25.8) 3 29 3 2 27
pT3 69 (55.6) 10 59 10 5 54
pT4 6 (4.9) 0 6 0 2 4
pN status 0.453 0.762
pN0 39 (31.5) 2 37 2 4 33
pN1 46 (37.1) 7 39 7 4 35
pN2 24 (19.3) 3 21 3 1 20
pN3 15 (12.1) 1 14 1 1 13
pM status 0.548 0.705
pM0 121(97.6) 13 108 13 10 98
pM1 3 (2.4) 0 3 0 0 3
Bold numbers represent P values with statistical significance
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variation in the extension of HER2 immunoreactive
areas in the equivocal category, ranging from 10 to 40 %
of tumor cells. In both categories, intratumoral protein
heterogeneity was mostly seen in mixed type carcin-
omas, in which HER2 expression highly correlated with
intestinal-type areas.
Apart from their HER2 score, many cases displayed a
cytoplasmic immunoreactivity in normal gastric mucosa
cells (87 cases, 70.2 %), metaplastic epithelium (30 cases,
24.2 %) and foci of dysplasia (24 cases, 19.4 %) (Fig. 2).
This pattern of expression was seen in both metaplastic
and dysplastic epithelium, despite the nature of the
metaplasia or the degree of the dysplasia. Nuclear ex-
pression was frequently seen among diffuse type carcin-
omas, but all these immunostained areas were not taken
into account for the scoring of the HER2 immunohisto-
chemical profile.
Discussion
In our study, we found a final HER2-positive status of
10.5 %. The overall HER2 positivity rate found in the
ToGA study was 810 of 3,665 patients (22.1 %) [6]. These
numbers represent one of the largest sets of HER2 testing
data in GC samples, obtained from patients from 24 differ-
ent countries in Asia, Europe and Latin America. Although
22.1 % accounts for more than double the amount of posi-
tive tumors we found in our series, the ToGA trial HER2
positivity screening criteria included all cases with protein
expression by IHC (3+ and 2+ cases) or gene amplification
by ISH alone. More detailed data concerning HER2 testing
in the ToGA study has been recently published revealing
that precisely 610 cases out of 3,665 tumor samples
(16.6 %) were in fact considered HER2 positive, by either
scoring IHC 3+ or IHC 2+ with gene amplification by
fluorescence in situ hybridization (FISH) [30]. A post hoc
exploratory analysis concluded that patients in those
categories were the ones who utterly benefited the most
from treatment with TZB [6]. Thus, the exact percentage
of patients eligible for treatment with TZB according to
HER2 screening performed on the ToGA trial was 16.6 %
and, when IHC results are considered alone, only 398 cases
(10.9 %) were actually HER2 positive (3+) [30]. In our
study, since no IHC 2+ cases showed gene amplification by
SISH, we found a IHC 3+ rate and a final HER2 positive
status of 10.5 %.
GC in Brazilian patients tends to arise in the antrum,
associated with Helicobacter pylori chronic infection,
therefore, our series is composed mainly of carcinomas
of the distal stomach (80.6 %). Since HER2 expression
has been greatly associated with GC of the cardia and
GEJ [17, 30–33], we expected to find an even lower posi-
tivity rate among our cases. ToGA trial results showed a
difference in HER2 positivity rates between Europe/Asia
and Central/South America (23.8 and 16.1 % respectively,
Fig. 1 Immunohistochemical analysis of HER2 expression in gastric carcinomas using the 4B5 antibody in whole-tissue sections. (a) a HER2-positive
case (3+); (b) a HER2-equivocal case (2+); (c) a HER2-negative case (1+); (d) intratumoral protein heterogeneity in a HER2-positive case (3+). (A-C: x400
field magnification; D: x200 field magnification)
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including all FISH-positive and IHC 3+ cases). The au-
thors associated the contrasting results as due to the lower
number of patients screened in Latin America (484 out of
3,665 patients) instead of a possible variation in tumor
biology [30]. Unfortunately, we could not find information
specifically regarding HER2 expression in GC of Brazilian
patients enrolled in the ToGA study. If cross-data between
tumor topography and patients’ countries of origin could
be retrieved, it might also help explain divergent HER2-
positive GC rates in Latin America.
Similar to our results, in a recent large European series
[34], as well as in a Japanese cohort of 1,461 patients [35],
there was no difference in HER2 positivity between prox-
imal and distal gastric tumors. However, two large Chinese
series [17, 33] recently showed significantly higher HER2
expression in proximal GC, in agreement with ToGA trial
findings [30] and with results from a series of 2,798 South
Korean patients [32]. The authors have implied that
intestinal-type cancers are usually more frequent in the
GEJ and, as different etiologies may play a role in car-
cinogenesis of tumors from these two locations, this
could partially justify distinct HER2 expression rates
according to tumor topography [30]. In addition to the
genetic ancestry according to ethnicity, multiple gastric
carcinogenesis pathways may be greatly influenced by
dietary habits and chronic Helicobacter pylori infection
[3]. Although this probably also has some influence on
HER2 positivity rates found in different populations with
GC, the relation between these factors and HER2 expres-
sion remains unknown, with few papers published [36, 37].
The number of IHC 3+ cases found in our study could
be explained in part by the fact that whole-tissue sec-
tions were exclusively used for HER2 evaluation, instead
of endoscopic biopsies. A recent study paired primary
gastrectomies and their endoscopic biopsies to compare
HER2 expression scores and found a concordance rate
of only 57 %, mostly due to intratumoral HER2 hetero-
geneity [38]. HER2 genetic heterogeneity by ISH has
been previously demonstrated on breast cancer, but it
seems to be a more complex issue on GC specimens
[39]. Protein expression heterogeneity by IHC, usually
referred as variability in immunohistochemical intensity
and extension of HER2-positive areas, is also a problem
which could greatly impact on sample selection for
HER2 testing in GC. In fact, HER2 expression hetero-
geneity has been demonstrated not only by our study
but also by other authors [39, 40], including a study
comprising 2,727 gastrectomies [32]. As a result, whole-
tissue sections obtained from resected primary gastric
tumors may offer a larger representation of different
sub clonal cancer cell population which could help
avoid false-negative results due to HER2 heterogeneity.
Since patients with locally advanced or metastatic GC
might not undergo primary gastrectomy, whole-tissue
sections are not always available and other GC samples
ought to be used instead, raising the question as to
which are the best suited for HER2 testing: endoscopic
biopsies versus metastatic lesions. For endoscopic biop-
sies, the recommendation is a viable number of repre-
sentative tumor fragments (ideally 6–8) and, if possible,
the pathologist should also perform HER2 testing on
another specimen when a negative result is found on a
tumor endoscopic biopsy [40].
In addition, GC samples from the ToGA trial were tested
for HER2 expression with the HercepTest kit, which uses a
rabbit polyclonal anti-HER2 antibody [6], whereas a rabbit
monoclonal antibody (4B5) was employed in our study.
Other studies have reported lower sensitivity rates for
HercepTest in comparison with 4B5 clone for the detec-
tion of HER2 protein expression [15, 41, 42]. This could
also account for the similar IHC 3+ percentage of cases
found in our series and on the ToGA trial, despite the pre-
dominance of tumors from the distal stomach among our
patients.
Data on HER2 expression in Brazilian patients with
GC are very limited and there is a wide variation on
published results. The first two studies ever conducted
in Brazil found a HER2 overexpression rate of 12 and
Fig. 2 Possible pitfalls in the immunohistochemical analysis of HER2
protein expression using the 4B5 antibody. Cytoplasmic non specific
staining in normal foveolar gastric mucosa (left) and in a focus of
gastric high-grade dysplasia (right) (x200 field magnification)
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5.4 %, including IHC 3+ and 2+ cases added together
[23, 24]. However, the grading score for breast cancer was
used for HER2 status assessment, in which the entire cell
membrane should be stained, and not only lateral or baso-
lateral walls, which suggests underestimation of HER2
positivity. In more recent research using specific HER2
scoring criteria for GC, IHC 3+ cases ranged from 0.8 % to
11.6 % [19–22, 25, 26]. Studies showing the lowest rates
(0.8 %, 3 % and 6 %) used tumor tissue microarrays
(TMAs) obtained from surgical specimens and other anti-
HER2 antibodies rather than 4B5 [19, 20, 22]. These results
are difficult to be compared with ours due to methodo-
logical differences, especially when TMAs and tumoral
protein expression heterogeneity are confronted. Thus,
TMAs could represent samples more similar to endoscopic
biopsies rather than to larger whole-tissue sections from
primary gastrectomies, which were used in our study.
Our results corroborate current literature findings on
Brazilian patients with GC tested for HER2 expression
using a highly sensitive anti-HER2 antibody in whole-tissue
tumor sections. As a matter of fact, a recent analysis from
a Brazilian cancer center compared the performance of
HercepTest, SP3 and 4B5 antibodies between whole-tissue
sections and TMAs in a series of 199 gastrectomies [21].
The authors found the highest HER2 positivity rate using
the same parameters of our study: 4B5 antibody in whole-
tissue tumor sections (11.6 %), a value most similar to our
finding (10.5 %). The lowest HER2 positivity rate was iden-
tified among TMAs and HercepTest kit (3 %) [21].
Despite the higher sensitivity found with the 4B5 anti-
body, some authors have also reported extensive cytoplas-
mic background staining of the gastric foveolar layer and
foci of intestinal metaplasia/dysplasia, as seen in our study,
which suggests an intrinsic clonal characteristic rather
than a methodological problem [15, 21, 41, 42]. In fact,
HER2 staining of dysplastic epithelium has been corre-
lated to gene amplification by ISH [43]. Although there
were no difficulties in distinguishing HER2-positive neo-
plastic cells from those areas, we stress that the staining of
the latter must not be considered when scoring HER2
expression.
Until the writing of the present manuscript the authors
were able to retrieve only three other studies regarding
ISH for gene amplification detection in GC samples from
Brazilian patients [19, 21, 25]. Begnami et al. found an
overall amplification rate of 8 % using FISH, but the per-
centage of IHC 2+ amplified cases was not mentioned [19].
Similar to our findings, another group did not find any
Table 2 HER2 expression in gastric cancer: analysing studies with patients from different parts of the world
Study Year Patients’ place of origin Number of patients HER2 positive rate (%) Association with clinicopathological features
Bang YJ [6] 2010 ToGA trial (Multicenter) 3,665 16.6 Topography (GEJ)
Intestinal-type
Begnami MD [19] 2011 Brazil (Single center) 221 8.0 Intestinal-type
Low-grade
Cruz-Reyes C [45] 2013 Mexico (Single center) 269 3.7 Intestinal-type




Higher lymph node stage
Advanced staging
Shan L [17] 2013 China (Single center) 1,463 9.8 Topography (GEJ)
Intestinal-type
Low-grade
Matsusaka S [35] 2015 Japan (Multicenter) 1,461 15.6 Intestinal-type
Hepatic metastasis
Absence of peritoneal metastasis
Cappellesso R [34] 2015 Europe (Multicenter) 1,040 11.0 Intestinal-type
Low-grade
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amplified cases among IHC 2+ tumors, although FISH was
the employed method [25]. Besides our study, only another
one applied silver brightfield dual ISH in IHC 2+ cases
[21]. Results showed a wide range of amplification rates
(from zero to 100 %), according to the primary antibody
used for IHC and tissue samples (whole-tissue sections ver-
sus TMAs). 4B5 antibody on 198 whole-tissue sections re-
vealed 20 cases with a equivocal HER2 score (10.1 %) of
which only 6 cases (30 %) showed gene amplification by
SISH [21]. The percentage of cases with a final HER2 posi-
tive status was 14.6 %, a slightly higher rate than the one
we uncovered, which could be partly due to the lower
frequency of distal GC (43.2 %) in their series. They have
concluded that the most accurate IHC method for evaluat-
ing HER2 expression in GC was to use the 4B5 antibody
on whole-tissue sections [21], which was exactly the
method employed in our study.
Moreover, we found an association between HER2
positive tumors and some pathological parameters, such
as Laurén’s intestinal subtype (P = 0.048), well to moder-
ately differentiated tumors (P = 0.004) and presence of
lymphovascular invasion (P = 0.031). The intestinal sub-
type has been proven to be the pathological feature most
invariably associated with HER2 positivity in multiple
studies [17, 32, 34, 35, 44, 45], including the ToGA trial
[30] and some with Brazilian patients [19, 22, 23, 26]. Since
HER2 positivity is expected to be found on intestinal-type
tumors, we strongly encourage that, when dealing with a
mixed-type tumor, areas showing an intestinal morphology
should be selected for HER2 scoring.
Association of HER2 positivity with histological grade
and presence of lymphovascular invasion has also been
reported by some authors [19, 25, 31, 46] but not by
others [20, 47]. A recent meta-analysis comprising 15
studies and 5,290 patients concluded that not only Lau-
rén’s classification system but also tumor differentiation
and lymphovascular invasion were associated with HER2
positivy [48]. Table 2 summarizes results from various
studies concerning HER2 positivity rates and the associ-
ation between HER2 expression with clinicopathological
features in patients with GC from different parts of the
world, in comparison to our findings.
Conclusions
Our study demonstrates a HER2-positive GC frequency of
10.5 % among Brazilian patients, analogous to rates ob-
served in different populations from studies applying simi-
lar methodology. Also, our findings showed an association
of HER2 positive status with Laurén’s intestinal subtype,
well to moderately differentiated tumors, and presence of
lymphovascular invasion, as it has been reported by other
authors. Finally, there was no association found with tumor
topography mainly due to the predominance of carcinomas
of the gastric antrum in our series, as expected among Bra-
zilian patients with GC.
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